On July 28, 2026, the FDA released revised draft product-specific guidances covering 17 generic peptide products, a technical but consequential step for any company hoping to eventually bring lower-cost generic versions of drugs like semaglutide and tirzepatide to market. The public comment period on the revisions closes September 28, 2026.
What a Product-Specific Guidance Actually Does
Product-specific guidances are documents the FDA issues for individual reference drugs, spelling out what a generic manufacturer needs to demonstrate, analytically and clinically, to prove its version is equivalent to the original. For small-molecule generics this process is relatively well established. Peptides sit in a more complicated middle ground: many are manufactured through recombinant, synthetic, or semi-synthetic processes that can introduce subtle structural differences a simple chemical comparison wouldn't catch, which is part of why the FDA treats peptide generics with a distinct set of expectations.
Which Drugs Are Covered
The 17 revised guidances span reference drugs used to treat type 2 diabetes, obesity, osteoporosis, and macular degeneration. Named reference products include semaglutide, tirzepatide, liraglutide, and teriparatide, meaning the revisions touch several of the drugs most discussed on this site.
What Changed
The FDA updated its recommendations across five technical areas: manufacturing submission expectations for recombinantly, synthetically, or semi-synthetically produced peptides; innate immune response testing, which screens for whether a peptide product might trigger unwanted immune reactions; impurity thresholds; higher-order structure assessment, meaning how a peptide's three-dimensional folding is verified to match the reference product; and biological activity evaluation. Separately, the agency withdrew its 2021 guidance on synthetic peptides that reference biologic-origin drugs, with a replacement expected later in 2026.
What It Means in Practice
For generic-drug manufacturers and the contract development organizations that support them, the revisions create clearer, more specific analytical expectations, which industry commentary has generally described as a positive step even though it may require some in-progress development programs to adjust their testing protocols. It does not, on its own, accelerate when generic semaglutide or tirzepatide might actually reach pharmacy shelves; as covered elsewhere on this site, patent protections on the current branded GLP-1 drugs mean true generic competition is still likely years away regardless of how clear the FDA's testing framework becomes. What this guidance does is reduce ambiguity for the manufacturers preparing to compete once those patents expire, and it signals that the agency is actively building out a regulatory pathway specifically suited to peptide generics rather than trying to force them through a small-molecule framework that doesn't fully fit.
What Happens Next
Because this is still a draft guidance, it is not yet binding, and the FDA is accepting public comments through September 28, 2026 before finalizing it. Manufacturers, patient advocacy groups, and other stakeholders can submit feedback during that window, and the agency may revise the document further based on what it receives before the guidance is finalized.
How This Fits the Broader Regulatory Picture
This revision doesn't exist in isolation. The FDA has been actively working through several peptide-specific regulatory questions this year, including a separate workshop on the generic GLP-1 drug pathway and ongoing review of which peptides belong on its bulk drug substance compounding lists, both covered elsewhere on this site. Taken together, these efforts suggest the agency is building out a more complete, peptide-specific regulatory framework, piece by piece, rather than treating peptide drugs as a one-off exception to existing small-molecule rules.